RecruitingNCT05924555

Exercise Intolerance Study in Long Chain Fatty Acid Oxidation Disorders


Sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Enrollment

50 participants

Start Date

Aug 1, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

In this study, the exercise tolerance in patients with long-chain fatty acid oxidation disorders (LcFAOD) will be compared to that of healthy volunteers who are carefully matched in terms of age, sex, BMI and physical activity score. The study aims to assess exercise capacity using cardiopulmonary exercise (CPX) tests and activity monitoring over a 7-day period. The hypothesis of the study is that LcFAOD patients will exhibit greater oxygen debt during short periods of exercise compared to healthy individuals. These findings will contribute to a better understanding of exercise intolerance in LcFAOD patients and may guide the development of targeted interventions, such as exercise training programs and enable the analysis of effectiveness of (new) treatments.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • LC-FAOD patients:
  • Men and women (age ≥18 years) with a confirmed diagnosis of carnitine palmitoyltransferase 2 (CPT2) deficiency, Carnitine-acylcarnitine translocase (CACT) deficiency, Mitochondrial Trifunctional protein (MTP) deficiency, Very-long-chain acyl-CoA dehydrogenase (VLCAD) deficiency or Long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency.
  • Healthy control subjects:
  • \- Healthy men and women age ≥ 18 years

Exclusion Criteria14

  • LcFAOD patients:
  • Pregnancy
  • Recent acute myocardial infarction (\<6 months prior to inclusion)
  • Uncontrolled arrhythmia/severe conduction disorder causing hemodynamic compromise
  • Implantable pacemaker or other cardiac device with complete ventricular pacing
  • Uncontrolled heart failure with hemodynamic compromise
  • Uncontrolled hypertension (Systolic Blood Pressure \>150 mmHg and Diastolic Blood Pressure \>100 mmHg on repeated measurements)
  • Active infection, anemia, severe renal dysfunction (estimated Glomerular filtration rate \< 30 ml/min/1,73m2), or other chronic disease likely to significantly impact exercise performance
  • History of severe asthma or chronic obstructive pulmonary disease
  • Active use of medication likely to affect exercise tolerance
  • Healthy controls:
  • History of smoking - History of asthma, chronic obstructive pulmonary disease, heart failure, heart surgery, heart rhythm disorders or congenital heart diseases
  • Chronic illness (including orthopedic, endocrinological, hematological, malignant, gastrointestinal, neurological, muscle or inflammatory disorders) likely to significantly impact on exercise performance
  • \> 6 alcohol units per day or \> 14 alcohol units per week

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERIntermittent cardiopulmonary exercise test

Exercise test with step-change from rest to a relatively low constant workload.

OTHERIncremental cardiopulmonary exercise test

Exercise test with incremental workload until maximal workload.

OTHEREchography of upper leg

Determine upper leg muscle size

OTHERHand grip strength with hand dynamometer

Determine muscle strength

OTHERFill in questionnaires regarding physical activity

SQUASH, mMRC, questionnaire designed to report myopathic symptoms in LcFAOD patients.


Locations(1)

Amsterdam UMC, location AMC

Amsterdam, North Holland, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05924555